ANIP Nasdaq Pharmaceuticals Financials FY2016βFY2025
ANI Pharmaceuticals had $883M of revenue in fiscal 2025, up 43.8% on the year before. Over five years, revenue changed +33.5% a year on average.
Hi! I read ANI Pharmaceuticalsβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+43.8%
Yes. Sales grew 43.8% last year.
Does it make a profit?
8.9%
A little. It keeps 8.9% of every sale as profit.
Does profit turn into cash?
19.4%
Yes. 19.4% of sales ends up as free cash.
Is debt under control?
0.1x
Yes. It could repay its debt with 0.1 years of operating profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
15.7x
One share costs 15.7 times its yearly profit per share. Typical for its sector: 28.4x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· ANI Pharmaceuticals had $883M of revenue in fiscal 2025, up 43.8% on the year before. Over five years, revenue changed +33.5% a year on average. Its operating margin was 12.6%, up 12.5Β pts: of every 100 in sales, about 13 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· ANI Pharmaceuticals made $78.3M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 28.8% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $171M in fiscal 2025, 19.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· ANI Pharmaceuticals returned $13.4M to shareholders in fiscal 2025, 8% of free cash flow. The diluted share count rose 9.9%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $15.5M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$15.5M
12 insiders
Of sales under plans
38%
$5.9M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Nikhil LalwaniPresident & CEO, Director | Sold plan | 5,400 | $71.89 | $0.4M | Form 4 |
| Oct 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $73.59 | $0.0M | Form 4 |
| Sep 29, 2026 | Stephen P. CareySVP & CFO | Sold plan | 2,850 | $73.00 | $0.2M | Form 4 |
| Sep 15, 2026 | Nikhil LalwaniPresident & CEO, Director | Sold plan | 5,400 | $71.00 | $0.4M | Form 4 |
| Sep 14, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $70.79 | $0.0M | Form 4 |
| Sep 11, 2026 | Jeanne ThomaDirector | Sold plan | 1,000 | $71.53 | $0.1M | Form 4 |
| Aug 31, 2026 | Stephen P. CareySVP & CFO | Sold plan | 2,850 | $72.80 | $0.2M | Form 4 |
| Aug 25, 2026 | Nikhil LalwaniPresident & CEO, Director | Sold plan | 5,400 | $74.30 | $0.4M | Form 4 |
| Aug 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $75.48 | $0.0M | Form 4 |
| Aug 10, 2026 | Ori GutwergSVP, Generics | Sold | 3,162 | $77.00 | $0.2M | Form 4 |
| Jul 29, 2026 | Stephen P. CareySVP & CFO | Sold plan | 2,850 | $81.36 | $0.2M | Form 4 |
| Jul 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $81.84 | $0.0M | Form 4 |
| Jul 2, 2026 | Stephen P. CareySVP & CFO | Sold plan | 3,313 | $86.00 | $0.3M | Form 4 |
| Jun 29, 2026 | Stephen P. CareySVP & CFO | Sold plan | 2,850 | $84.12 | $0.2M | Form 4 |
| Jun 12, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $82.03 | $0.0M | Form 4 |
| Jun 8, 2026 | Thomas HaugheyDirector | Sold plan | 2,000 | $80.88 | $0.2M | Form 4 |
| Jun 5, 2026 | Stephen P. CareySVP & CFO | Sold plan | 3,312 | $80.00 | $0.3M | Form 4 |
| May 13, 2026 | Patrick D WalshDirector | Sold | 10,000 | $80.63 | $0.8M | Form 4 |
| May 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $78.16 | $0.0M | Form 4 |
| May 12, 2026 | Thomas Andrew RowlandSVP, Head - Established Brands | Sold | 459 | $79.21 | $0.0M | Form 4 |
| May 12, 2026 | Ori GutwergSVP, Generics | Sold | 2,772 | $79.50 | $0.2M | Form 4 |
| May 11, 2026 | Nikhil LalwaniPresident & CEO, Director | Sold | 55,000 | $77.57 | $4.3M | Form 4 |
| May 11, 2026 | Patrick D WalshDirector | Sold | 3,973 | $80.75 | $0.3M | Form 4 |
| Apr 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $77.95 | $0.0M | Form 4 |
| Mar 13, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 3,162 | $71.64 | $0.2M | Form 4 |
| Mar 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $72.62 | $0.0M | Form 4 |
| Mar 11, 2026 | Thomas Andrew RowlandSVP, Head - Established Brands | Sold | 4,772 | $74.91 | $0.4M | Form 4 |
| Mar 9, 2026 | Krista DavisSVP, Chief HR Officer | Sold plan | 5,087 | $74.13 | $0.4M | Form 4 |
| Mar 9, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 3,602 | $74.18 | $0.3M | Form 4 |
| Mar 6, 2026 | Krista DavisSVP, Chief HR Officer | Sold plan | 1,485 | $75.00 | $0.1M | Form 4 |
| Mar 6, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 2,121 | $74.22 | $0.2M | Form 4 |
| Mar 5, 2026 | Stephen P. CareySVP & CFO | Sold | 7,312 | $75.50 | $0.6M | Form 4 |
| Mar 3, 2026 | Ori GutwergSVP, Generics | Sold | 2,060 | $76.50 | $0.2M | Form 4 |
| Mar 3, 2026 | Patrick D WalshDirector | Sold | 6,000 | $74.23 | $0.4M | Form 4 |
| Mar 2, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 417 | $74.00 | $0.0M | Form 4 |
| Feb 20, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 5,323 | $78.02 | $0.4M | Form 4 |
| Feb 20, 2026 | Krista DavisSVP, Chief HR Officer | Sold plan | 1,730 | $77.99 | $0.1M | Form 4 |
| Feb 19, 2026 | Krista DavisSVP, Chief HR Officer | Sold plan | 2,084 | $77.53 | $0.2M | Form 4 |
| Feb 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $76.80 | $0.0M | Form 4 |
| Feb 12, 2026 | Christopher MutzHead of Rare Disease | Sold plan | 7,032 | $76.55 | $0.5M | Form 4 |
| Jan 13, 2026 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 500 | $84.33 | $0.0M | Form 4 |
| Dec 18, 2025 | Krista DavisSVP, Chief HR Officer | Sold plan | 1,622 | $82.40 | $0.1M | Form 4 |
| Dec 12, 2025 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 400 | $82.32 | $0.0M | Form 4 |
| Dec 5, 2025 | Renee P TannenbaumDirector | Sold | 1,800 | $81.15 | $0.1M | Form 4 |
| Nov 13, 2025 | Patrick D WalshDirector | Sold | 8,643 | $86.88 | $0.8M | Form 4 |
| Nov 13, 2025 | Chad GassertSVP - Corp. Dev. & Strategy | Sold | 94 | $88.00 | $0.0M | Form 4 |
| Nov 13, 2025 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 400 | $87.27 | $0.0M | Form 4 |
| Nov 12, 2025 | Chad GassertSVP - Corp. Dev. & Strategy | Sold | 14,642 | $89.07 | $1.3M | Form 4 |
| Oct 13, 2025 | Meredith CookSr. VP, General Counsel & Sec. | Sold plan | 400 | $90.09 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· ANI Pharmaceuticals owes $23.7M more than it holds in cash, about 0.1 years of operating profit.
Cash, debt and the ratios that show how comfortably ANI Pharmaceuticals can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $100M | $48.2M | $221M | $145M | $286M |
| Debt incl. finance leases | $287M | $287M | $286M | $319M | $309M |
| Net debt / EBITDA | 25.1x | 11.0x | 0.6x | 2.5x | 0.1x |
| Debt / equity | 0.9x | 0.9x | 0.7x | 0.8x | 0.6x |
| Interest coverage | β3.3x | β1.2x | 1.3x | 0.0x | 3.4x |
| Current ratio | 3.7x | 3.5x | 3.6x | 2.7x | 2.7x |
| Quick ratio | 2.7x | 2.4x | 2.8x | 2.0x | 2.2x |
| Total assets | $772M | $760M | $904M | $1.3B | $1.4B |
| Total liabilities | $413M | $422M | $447M | $856M | $900M |
| Shareholders' equity | $334M | $314M | $433M | $404M | $541M |
| Net debt (β = net cash) | $187M | $238M | $64.6M | $174M | $23.7M |
KIRA Β· Its return on capital was 15.9%: every 100 invested in the business earned about 16 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· ANI Pharmaceuticals passes 6 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 7 / 8 | 4 / 8 | 6 / 8 |
| Accruals ratio | β12.0% | β7.5% | β7.9% |
| Altman Z'' | 3.79 | 1.95 | 3.26 |
What does the share cost, and how does it compare?
KIRA Β· At $72.61 a share, the company is worth $1.6B: 15.7 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of β$23.7M and divides by 21.2M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 15.7x Β· peers 14.9x Β· sector 28.4x.
KIRA Β· ANI Pharmaceuticals grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 2 of 3.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 | |
| Collegium Pharmaceutical COLL | $746M | 23.6% | 23.0% | 42.0% | 53.4% | 18.5x | 6 | Compare β |
| Corcept Therapeutics CORT | $10.2B | 12.8% | 5.9% | 18.6% | 15.7% | β | 3 | Compare β |
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | β | 8.8x | β | Compare β |
| Amphstar Pharmaceuticals AMPH | $1.1B | β1.7% | 19.5% | 16.8% | 9.9% | 14.9x | 6 | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $129M | $177M | $202M | $207M | $209M | $216M | $316M | $487M | $614M | $883M |
| Gross profit | $79.8M | $97.8M | $129M | $143M | $121M | β | β | β | β | β |
| Research and development | $2.9M | $9.1M | $15.4M | $19.8M | $16.0M | $11.4M | $22.3M | $34.3M | $44.6M | $51.7M |
| Operating income | $20.1M | $28.3M | $35.4M | $16.4M | β$16.0M | β$39.8M | β$35.3M | $47.0M | $0.6M | $111M |
| Interest expense | $11.3M | $11.3M | $14.9M | $13.5M | $9.5M | $11.9M | $28.5M | $35.6M | $33.6M | $32.6M |
| Pretax income | $8.7M | $16.3M | $20.1M | $3.2M | β$26.0M | β$56.1M | β$62.7M | $19.9M | β$22.2M | $95.8M |
| Income tax | $4.7M | $17.4M | $4.6M | β$2.9M | β$3.4M | β$13.5M | β$14.8M | $1.1M | β$3.7M | $17.5M |
| Net income | $3.9M | β$1.1M | $15.5M | $6.1M | β$22.5M | β$42.6M | β$47.9M | $18.8M | β$18.5M | $78.3M |
| Diluted EPS | $0.34 | β$0.09 | $1.30 | $0.50 | β$1.88 | β$3.40 | β$3.05 | $0.85 | β$1.04 | $3.32 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | $27.5M | $39.4M | $67.1M | $45.6M | $15.3M | $3.3M | β$31.2M | $119M | $64.0M | $185M |
| Capital expenditure | $4.6M | $10.4M | $5.7M | $6.6M | $6.1M | $2.6M | $8.9M | $8.9M | $16.2M | $13.8M |
| Free cash flow | $22.9M | $29.1M | $61.3M | $39.0M | $9.1M | $0.8M | β$40.1M | $110M | $47.8M | $171M |
| Depreciation and amortization | $22.3M | $27.9M | $33.7M | $44.6M | $44.6M | $47.3M | $57.0M | $59.8M | $67.7M | $91.4M |
| Stock-based compensation | $6.1M | $6.1M | $6.8M | $9.2M | $12.9M | $10.5M | $14.6M | $20.7M | $29.3M | $37.9M |
| Acquisitions | $0.0M | $0.0M | $16.5M | $0.0M | $0.0M | $84.5M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $2.5M | $0.0M | $0.0M | $1.0M | $1.5M | $0.9M | $2.0M | $5.0M | $11.0M | $12.2M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M | $1.6M | $1.6M | $1.6M | $1.2M |
| Dividends and buybacks | $2.5M | $0.0M | $0.0M | $1.0M | $1.5M | $1.1M | $3.6M | $6.6M | $12.6M | $13.4M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $27.4M | $31.1M | $43.0M | $62.3M | $7.9M | $100M | $48.2M | $221M | $145M | $286M |
| Total debt | $121M | $128M | $70.6M | $186M | $186M | $287M | $287M | $286M | $318M | $309M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.4M | $0.2M |
| Current assets | $103M | $132M | $153M | $188M | $170M | $322M | $344M | $520M | $529M | $753M |
| Current liabilities | $31.9M | $39.2M | $166M | $61.7M | $78.6M | $87.5M | $99.4M | $146M | $195M | $278M |
| Inventory | $26.2M | $37.7M | $40.5M | $48.2M | $60.8M | $81.7M | $105M | $111M | $137M | $143M |
| Property and equipment, net | $11.0M | $20.4M | $38.1M | $40.6M | $41.3M | $52.7M | $43.2M | $44.6M | $56.9M | $62.5M |
| Total assets | $323M | $412M | $431M | $457M | $461M | $772M | $760M | $904M | $1.3B | $1.4B |
| Total liabilities | $153M | $237M | $233M | $244M | $266M | $413M | $422M | $447M | $856M | $900M |
| Shareholders' equity | $170M | $175M | $197M | $213M | $196M | $334M | $314M | $433M | $404M | $541M |
| Margins | ||||||||||
| Gross margin | 62.1% | 55.3% | 63.8% | 69.4% | 58.2% | β | β | β | β | β |
| Operating margin | 15.6% | 16.0% | 17.5% | 7.9% | β7.7% | β18.4% | β11.2% | 9.7% | 0.1% | 12.6% |
| EBITDA margin | 33.0% | 31.8% | 34.3% | 29.5% | 13.7% | 3.5% | 6.9% | 21.9% | 11.1% | 22.9% |
| Net margin | 3.1% | β0.6% | 7.7% | 3.0% | β10.8% | β19.7% | β15.1% | 3.9% | β3.0% | 8.9% |
| FCF margin | 17.8% | 16.4% | 30.4% | 18.9% | 4.4% | 0.4% | β12.7% | 22.6% | 7.8% | 19.4% |
| Returns | ||||||||||
| Return on capital | 5.3% | 5.3% | 11.0% | 5.8% | β3.6% | β7.0% | β5.2% | 8.5% | 0.1% | 15.9% |
| Return on capital employed | 7.1% | 8.5% | 11.1% | 5.0% | β4.1% | β7.5% | β5.3% | 6.6% | 0.1% | 9.9% |
| Return on equity | 2.4% | β0.6% | 8.3% | 3.0% | β11.0% | β16.1% | β14.8% | 5.0% | β4.4% | 16.6% |
| Return on assets | 1.3% | β0.3% | 3.7% | 1.4% | β4.9% | β6.9% | β6.3% | 2.3% | β1.7% | 5.8% |
| Growth | ||||||||||
| Revenue growth | 68.5% | 37.5% | 14.0% | 2.5% | 0.9% | 3.7% | 46.4% | 53.9% | 26.2% | 43.8% |
| Net income growth | β74.4% | β127.4% | β | β60.7% | β470.0% | β | β | β | β198.6% | β |
| EPS growth | β74.2% | β126.5% | β | β61.5% | β476.0% | β | β | β | β222.4% | β |
| FCF growth | 51.9% | 26.8% | 111.1% | β36.4% | β76.6% | β91.6% | β5,339.1% | β | β56.6% | 258.7% |
| Share count change | 0.1% | β0.2% | 2.0% | 2.3% | β0.6% | 5.3% | 29.1% | 11.9% | 6.2% | 9.9% |
| Financial health | ||||||||||
| Net debt / EBITDA | 2.2x | 1.7x | 0.4x | 2.0x | 6.2x | 25.1x | 11.0x | 0.6x | 2.5x | 0.1x |
| Debt / equity | 0.7x | 0.7x | 0.4x | 0.9x | 1.0x | 0.9x | 0.9x | 0.7x | 0.8x | 0.6x |
| Interest coverage | 1.8x | 2.5x | 2.4x | 1.2x | β1.7x | β3.3x | β1.2x | 1.3x | 0.0x | 3.4x |
| Current ratio | 3.2x | 3.4x | 0.9x | 3.0x | 2.2x | 3.7x | 3.5x | 3.6x | 2.7x | 2.7x |
| Quick ratio | 2.4x | 2.4x | 0.7x | 2.3x | 1.4x | 2.7x | 2.4x | 2.8x | 2.0x | 2.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.6% | 5.9% | 2.9% | 3.2% | 2.9% | 1.2% | 2.8% | 1.8% | 2.6% | 1.6% |
| Stock comp / revenue | 4.7% | 3.4% | 3.4% | 4.5% | 6.2% | 4.9% | 4.6% | 4.2% | 4.8% | 4.3% |
| Payouts / FCF | 10.9% | 0.0% | 0.0% | 2.6% | 16.7% | 141.2% | β | 6.0% | 26.3% | 7.8% |
| Quality scores | ||||||||||
| Piotroski F-score | 5.0 | 6.0 | 6.0 | 5.0 | 4.0 | 4.0 | 3.0 | 7.0 | 4.0 | 6.0 |
| Altman Z'' | 3.0 | 2.7 | 1.3 | 3.1 | 1.8 | 2.3 | 2.2 | 3.8 | 2.0 | 3.3 |
| Accruals ratio | β7.7% | β11.0% | β12.2% | β8.9% | β8.2% | β7.5% | β2.2% | β12.0% | β7.5% | β7.9% |
Source: SEC EDGAR XBRL filings (CIK 0001023024). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
